论文部分内容阅读
目的探讨艾迪注射液与FOLFOX-4联用方案在结直肠癌根治术后的临床应用。方法选取2009年5月～2011年2月在某院治疗的63例直肠癌根治术后化疗患者为研究对象,随机分为实验组(艾迪注射液与FOLFOX-4联用方案组)32例和对照组(单用FOLFOX-4组)31例,比较两组结直肠癌患者化疗后KBS生活质量评分、体质量变化以及出现化疗药物的毒副作用的患者比例。结果实验组治疗后KBS评分升高大于10分(提高)的患者比例为68.8%、体质量增加的患者比例为65.6%,均明显高于对照组;消化道反应在2级以上的比例为21.9%,神经毒性在2级以上的比例为3.1%,肝功能损伤在2级以上的比例为18.8%,血液毒性在2级以上的比例为6.3%,均明显低于对照组。以上差异均有统计学上的意义,P﹤0.05。结论艾迪注射液能够显著的降低结直肠癌根治术后患者应用FOLFOX-4化疗方案的毒副反应,同时能够提高患者的生活质量及体质,可以在临床推广。
Objective To investigate the clinical application of Aidi Injection combined with FOLFOX-4 in the treatment of colorectal cancer after radical operation. Methods Sixty-three patients undergoing radical resection of rectal cancer treated in a hospital from May 2009 to February 2011 were selected and randomly divided into experimental group (Aidi Injection and FOLFOX-4 combined with the program group) in 32 cases And control group (FOLFOX-4 alone). The proportions of patients with colorectal cancer after chemotherapy for KBS quality of life, body mass changes and the side effects of chemotherapy drugs were compared between the two groups. Results The KBS score increased more than 10 points (improved) in the experimental group, the proportion of patients was 68.8%, and the increase of body weight was 65.6%, which was significantly higher than that of the control group. The proportion of digestive tract reactions above grade 2 was 21.9 %, The ratio of neurotoxicity above grade 2 was 3.1%, the percentage of liver function damage above grade 2 was 18.8%, and the rate of blood toxicity above grade 2 was 6.3%, which were significantly lower than that of the control group. The above differences were statistically significant, P <0.05. Conclusion Aidi Injection can significantly reduce the side effects of FOLFOX-4 chemotherapy in patients with colorectal cancer after radical operation, and can improve the quality of life and physique of patients, which can be clinically promoted.